
NEWS
October, 02, 2026
Telesis Bio Featured in Forbes on AI, Biotech and the Future of DNA Synthesis
In a Forbes article on AI adoption across biotech and pharma, Telesis Bio CEO Eric Esser discusses the need to turn digital designs into physical molecules for validation. He describes how the Gibson SOLA® platform helps labs make gene-length DNA in-house and on demand, connecting AI-driven design with experimental discovery.
August 25, 2026
SAN DIEGO, Calif. — Telesis Bio® Inc., maker of the world’s only intelligent, on-premises DNA synthesis solution for AI labs, today announced recent commercial licensing agreements with several AI-native drug discovery companies. The agreements reflect a growing understanding that integrating…
May 28, 2025
New technology has potential to accelerate timelines for therapeutic research and drug development SAN DIEGO–(BUSINESS WIRE)–May 28, 2025– Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated…


About Telesis Bio
Telesis Bio enables researchers to eliminate outsourcing delays and boost productivity by enabling rapid, on-site synthesis of high-fidelity DNA and mRNA with its Gibson SOLA® platform. Designed to integrate with standard lab automation, Gibson SOLA gives scientists full control over build timelines and IP. From antibodies to cell therapies, innovators across biotech and pharma use Telesis Bio to accelerate development in synthetic biology and therapeutic discovery.
©2026 Telesis Bio Inc. All rights reserved.